Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance

Trial Profile

Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance

Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Jun 2018

At a glance

  • Drugs RP G28 (Primary)
  • Indications Lactose intolerance
  • Focus Registrational; Therapeutic Use
  • Sponsors Ritter Pharmaceuticals
  • Most Recent Events

    • 27 Jun 2018 According to a Ritter Pharmaceuticals media release,Status changed from not yet recruiting to recruiting.
    • 27 Jun 2018 According to a Ritter Pharmaceuticals media release, first patient has been enrolled in this trial.
    • 10 May 2018 Planned number of patients changed from 500 to 525.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top